Treatment with MDL 72527 Ameliorated Clinical Symptoms, Retinal Ganglion Cell Loss, Optic Nerve Inflammation, and Improved Visual Acuity in an Experimental Model of Multiple Sclerosis

Treatment with MDL 72527 Ameliorated Clinical Symptoms, Retinal Ganglion Cell Loss, Optic Nerve Inflammation, and Improved Visual Acuity in an Experimental Model of Multiple Sclerosis

Multiple Sclerosis (MS) is a highly disabling neurological disease characterized by inflammation, neuronal damage, and demyelination. Vision impairment is one of the major clinical features of MS. Previous studies from our lab have shown that MDL 72527, a pharmacological inhibitor of spermine oxidas...

Full description

Bibliographic Details
Main Authors: Fang Liu, Moaddey Alfarhan, Leanna Baker, Nidhi Shenoy, Yini Liao, Harry O. Henry-Ojo, Payaningal R. Somanath, S. Priya Narayanan
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Cells
Subjects:
multiple sclerosis
vision
neurodegeneration
inflammation
optic neuritis
experimental autoimmune encephalomyelitis
Online Access:https://www.mdpi.com/2073-4409/11/24/4100

Internet

https://www.mdpi.com/2073-4409/11/24/4100

Similar Items